You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
SOBERANA, Cuba's COVID-19 Vaccine Candidates: Dagmar García-Rivera PhD.
|
|---|---|
| Published in |
MEDICC Review, January 2020
|
| DOI | 10.37757/mr2020.v22.n4.11 |
| Pubmed ID | |
| Authors |
Conner Gorry |
| Abstract |
On August 13, 2020, Cuba's national regulatory agency, the Center for Quality Control of Medicines, Equipment and Medical Devices (CECMED), authorized clinical trials for SOBERANA 01-Cuba's fi rst vaccine candidate and the fi rst from Latin America and the Caribbean. On August 24, parallel Phase I/II double blind, randomized, controlled clinical trials were launched at clinical sites in Havana to evaluate the vaccine's safety and immunogenicity. Analysis of results and development of different formulations are currently under way and Phase III clinical trials are planned for early 2021. At the time of writing, a second vaccine candidate, SOBERANA 02, was in late-stage development and preparing to begin separate trials this fall. |
X Demographics
The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 12% |
| Italy | 1 | 6% |
| United States | 1 | 6% |
| Côte d'Ivoire | 1 | 6% |
| Colombia | 1 | 6% |
| Brazil | 1 | 6% |
| Unknown | 10 | 59% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 17 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 59 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 13 | 22% |
| Student > Ph. D. Student | 6 | 10% |
| Student > Master | 5 | 8% |
| Student > Doctoral Student | 4 | 7% |
| Researcher | 3 | 5% |
| Other | 8 | 14% |
| Unknown | 20 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 20% |
| Biochemistry, Genetics and Molecular Biology | 7 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 12% |
| Nursing and Health Professions | 4 | 7% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 9 | 15% |
| Unknown | 18 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 45. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 February 2023.
All research outputs
#943,630
of 25,761,363 outputs
Outputs from MEDICC Review
#9
of 220 outputs
Outputs of similar age
#22,987
of 480,009 outputs
Outputs of similar age from MEDICC Review
#1
of 18 outputs
Altmetric has tracked 25,761,363 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 220 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 480,009 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.